All Updates

All Updates

icon
Filter
Partnerships
Sarepta partners with Arrowhead Pharmaceuticals to develop rare genetic disease treatments
Cell & Gene Therapy
Nov 27, 2024
This week:
Partnerships
AML3D partners with Tennessee Valley Authority to provide advanced additive manufacturing system
Additive Manufacturing
Today
Industry news
Bragar Eagel & Squire files class action lawsuit against Symbotic
Logistics Tech
Today
Product updates
Silverfort launches Privileged Access Security for identity protection
Identity & Access Management
Yesterday
Product updates
RSA launches passwordless authentication app and security key
Identity & Access Management
Yesterday
Partnerships
SonicWall partners with CrowdStrike to offer managed detection and response for SMBs
Next-gen Cybersecurity
Yesterday
Product updates
Industry news
Axiom Space launches Ax-4 mission with international astronauts
Space Travel and Exploration Tech
Yesterday
Partnerships
SpaceX partners with US DoD to provide Starshield satellite access to Ukraine
Next-gen Satellites
Yesterday
Funding
SES Space & Defense secures USD 117 million DoD contract for European satellite services
Next-gen Satellites
Yesterday
Funding
Friend raises USD 5.4 million in seed funding to develop AI companion platform
Generative AI Applications
Yesterday
Product updates
Remote launches Recruit AI for global talent matching
Remote Work Infrastructure
Yesterday
Cell & Gene Therapy

Cell & Gene Therapy

Nov 27, 2024

Sarepta partners with Arrowhead Pharmaceuticals to develop rare genetic disease treatments

Partnerships

  • Massachusetts-based gene therapy company Sarepta Therapeutics and California-based biopharmaceutical company Arrowhead Pharmaceuticals have entered a global licensing and partnership deal focused on developing treatments for rare genetic diseases.

  • Under the agreement, Arrowhead will receive USD 825 million, consisting of USD 500 million in cash and USD 325 million as an equity investment. Arrowhead will also receive USD 250 million to be paid in equal installments over five years, a potential additional USD 300 million in near-term payments, up to USD 10 billion in milestone payments, and royalties on sales.

  • The licensing agreement includes four clinical-stage programs, three preclinical candidates, and up to six potential discovery programs. Arrowhead will use its Targeted RNAi Molecule (TRiM) platform to conduct discovery and preclinical development activities. Sarepta will conduct the clinical development and commercialization activities of the resulting programs. The deal is expected to be finalized in early 2025.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.